A new narrative comparative review published in Cureus tackles the question dermatologists keep asking: how safe are Janus kinase (JAK) inhibitors over the long haul, and do dermatologic patients carry the same risk profile as rheumatologic ones?

The review examines three safety domains that have shadowed the JAK inhibitor class since its entry into dermatology — cardiovascular events, thromboembolism, and malignancy — across populations treated for skin disease and for rheumatologic disease. It's a comparative framing, not a single trial readout, and that distinction matters for how clinicians should use it.

Why dermatology cares now

JAK inhibitors have expanded from rheumatoid arthritis into the dermatologic armamentarium, with agents now approved for inflammatory skin conditions. That expansion brought rheumatology's safety baggage along with it — the class-wide warnings on major adverse cardiovascular events, venous thromboembolism, and malignancy that regulators attached after comparative safety data emerged in rheumatoid arthritis populations.

But dermatologic patients aren't rheumatoid arthritis patients. They differ in baseline cardiovascular risk, age distribution, concomitant immunosuppression, and disease-related inflammation exposure. The review's core contribution is placing the dermatologic evidence alongside the rheumatologic evidence and asking whether the safety signals transfer.

What the review covers

The authors conducted a narrative — not systematic — comparative review of long-term safety outcomes across the three domains:

• Cardiovascular safety — major adverse cardiovascular events in JAK inhibitor–treated populations
• Thromboembolic risk — venous thromboembolism and related events
• Malignancy risk — solid and hematologic malignancies during extended treatment

By synthesizing across both specialties, the review aims to give prescribers a class-level view rather than a drug-by-drug patchwork. As a narrative review, it weights the authors' interpretation of the literature rather than a protocol-driven meta-analysis, so readers should treat its conclusions as expert synthesis of existing evidence, not new primary data.

What does this change for the dermatology clinic?

The practical value is contextualization. Dermatologists prescribing JAK inhibitors have largely inherited risk estimates generated in rheumatologic cohorts — older patients, higher baseline cardiovascular risk, prior exposure to methotrexate and biologics. If the dermatologic populations show a different long-term safety picture, that changes counseling, monitoring intensity, and candidate selection at the prescription desk.

The review also lands at a moment when shared decision-making documentation for JAK inhibitors has become standard practice: the class's boxed warnings require a patient-level discussion of cardiovascular, thromboembolic, and malignancy risk before initiation. A comparative synthesis that separates dermatologic from rheumatologic signals gives clinicians better material for those conversations.

Limits to keep in mind

Narrative reviews carry known constraints. Study selection isn't protocol-driven, heterogeneity across trials can't be formally pooled, and publication bias can't be quantified the way a meta-analysis allows. The findings here should steer clinical judgment, not substitute for the trial-level data behind each agent's label.

For Derm Field readers, the takeaway is straightforward: the long-term safety of JAK inhibitors in skin disease remains an actively synthesized question, and this Cureus review consolidates what's known across specialties while making clear where the dermatology-specific evidence still needs to mature. Expect the comparative picture to sharpen as dermatologic registries and post-marketing surveillance generate longer-term data in skin-disease populations specifically.